Jaracz Jan, Gattner Karolina, Moczko Jerzy, Hauser Joanna
Department of Adult Psychiatry, Poznań University of Medical Sciences, ul. Szpitalna 27/33 60-572 Poznań, Poland.
Department of Adult Psychiatry, Poznań University of Medical Sciences, ul. Szpitalna 27/33 60-572 Poznań, Poland.
Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):36-9. doi: 10.1016/j.genhosppsych.2014.10.005. Epub 2014 Oct 20.
Unexplained painful physical symptoms are commonly reported by depressed patients. The evidence suggests that dual-action antidepressants are potent in relieving pain in depression. However, a direct comparison of the effects of selective serotonergic and selective noradrenergic antidepressants on painful symptoms has not been investigated so far.
Sixty patients who participated in the Genome-based Therapeutic Drugs for Depression study with a diagnosis of moderate or severe episodes of depression according to the International Classification of Diseases, 10th Revision, and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria were involved. All the participants were randomly allocated to receive nortriptyline or escitalopram. The severity of depression was measured using the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Beck Depression Inventory at weeks 0, 2, 4, 6 and 8. The intensity of pain was measured on the Visual Analog Scale at the same points of the study.
At "week 0," 83.3% of the patients later randomized to treatment with escitalopram and 86.7% of those treated with nortriptyline reported at least one painful symptom. A significant decrease of pain intensity was observed after 2 weeks of treatment. The two groups did not differ in degree of pain reduction at weeks 2, 4, 6 and 8 in comparison to baseline values. A 50% reduction in pain intensity preceded the 50% reduction of depression severity. The intensity of pain at "week 0" did not differ in remitted or nonremitted patients at week 8.
Both selective serotonergic and selective noradrenergic antidepressants are equally effective in alleviations of painful physical symptoms of depression. The presence of painful symptoms before the onset of treatment did not determine the final response.
抑郁症患者常报告有无法解释的疼痛性躯体症状。有证据表明,双通道抗抑郁药在缓解抑郁症疼痛方面效果显著。然而,迄今为止,尚未对选择性5-羟色胺能和选择性去甲肾上腺素能抗抑郁药对疼痛症状的影响进行直接比较。
60名参与基于基因组的抑郁症治疗药物研究的患者,根据《国际疾病分类》第10版和《精神疾病诊断与统计手册》第四版标准,被诊断为中度或重度抑郁症发作。所有参与者被随机分配接受去甲替林或艾司西酞普兰治疗。在第0、2、4、6和8周,使用蒙哥马利-阿斯伯格抑郁评定量表、汉密尔顿抑郁评定量表和贝克抑郁量表测量抑郁严重程度。在研究的相同时间点,使用视觉模拟量表测量疼痛强度。
在“第0周”,后来随机接受艾司西酞普兰治疗的患者中有83.3%,接受去甲替林治疗的患者中有86.7%报告至少有一种疼痛症状。治疗2周后,疼痛强度显著降低。与基线值相比,两组在第2、4、6和8周的疼痛减轻程度没有差异。疼痛强度降低50%先于抑郁严重程度降低50%。在第8周,缓解或未缓解的患者在“第0周”的疼痛强度没有差异。
选择性5-羟色胺能和选择性去甲肾上腺素能抗抑郁药在缓解抑郁症疼痛性躯体症状方面同样有效。治疗开始前疼痛症状的存在并不能决定最终的疗效。